Dutch regulatory authority rejects Cortiment (Cosmo/Ferring) for Ulcerative Colitis - 11-Aug-2012

Cosmo Pharmaceuticals received a communication from the Dutch Regulatory Agency (MEB) declining the approval of Cortiment(budesonide with MMX technology), indi­ca­ted for the induction of remission in patients with active, mild to moderate Ulce­ra­tive Colitis. The reasons given for the decline were on the grounds of clinical relevance. Cosmo is awaiting the formal letter to get full disclosure of the reasons for this decision. Santarus has filed the drug as Uceris at the FDA. Ferring have ROW rights licensed from Cosmo except for the US and Japan.

Related News

Related Gastroenterology Information

Related Gastroenterology Drugs

Back to top

Latest News

18 Jun 2013
18 Jun 2013
17 Jun 2013